These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 22968848)
1. Lack of current implantable cardioverter defibrillator guidelines application for primary prevention of sudden cardiac death in Latin American patients with heart failure: a cross-sectional study. Gonzalez-Zuelgaray J; Pellizon O; Muratore CA; Oropeza ES; Rabinovich R; Ramos JL; Tentori MC; Reyes N; Aguayo R; Marin J; Peterson BJ Europace; 2013 Feb; 15(2):236-42. PubMed ID: 22968848 [TBL] [Abstract][Full Text] [Related]
2. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death. Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108 [TBL] [Abstract][Full Text] [Related]
3. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience. Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676 [TBL] [Abstract][Full Text] [Related]
4. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. Sanders GD; Kong MH; Al-Khatib SM; Peterson ED Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982 [TBL] [Abstract][Full Text] [Related]
7. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers]. Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196 [TBL] [Abstract][Full Text] [Related]
8. Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry. Pedretti RF; Curnis A; Massa R; Morandi F; Tritto M; Manca L; Occhetta E; Molon G; De Ferrari GM; Sarzi Braga S; Raciti G; Klersy C; Salerno-Uriarte JA; Europace; 2010 Aug; 12(8):1105-11. PubMed ID: 20400768 [TBL] [Abstract][Full Text] [Related]
9. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403 [TBL] [Abstract][Full Text] [Related]
10. Frequency and determinants of implantable cardioverter defibrillator deployment among primary prevention candidates with subsequent sudden cardiac arrest in the community. Narayanan K; Reinier K; Uy-Evanado A; Teodorescu C; Chugh H; Marijon E; Gunson K; Jui J; Chugh SS Circulation; 2013 Oct; 128(16):1733-8. PubMed ID: 24048201 [TBL] [Abstract][Full Text] [Related]
11. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death. Boriani G; Gasparini M; Lunati M; Santini M; Landolina M; Vincenti A; Curnis A; Bocchiardo M; Padeletti L; Biffi M; Allaria L; Denaro A; Am Heart J; 2006 Sep; 152(3):527.e1-11. PubMed ID: 16923425 [TBL] [Abstract][Full Text] [Related]
12. [Remarks on the guideline recommendations for cardioverter-defibrillator implantation for primary prevention of sudden cardiac Death in patients with severe ventricular dysfunction. Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO)/Italian Society of Cardiology (SIC)/Italian Association of Arrhythmology and Cardiac Pacing (AIAC)]. Berisso MZ; Bongiorni MG; Curnis A; Calvi V; Catanzariti D; Gaita F; Gulizia MM; Inama G; Landolina ME; La Rovere MT; Mantovan R; Mascioli G; Occhetta E; Padeletti L; Salerno-Uriarte JA; Santini M; Sassone B; Senni M; Zecchin M G Ital Cardiol (Rome); 2013 Nov; 14(11):752-72. PubMed ID: 24326639 [TBL] [Abstract][Full Text] [Related]
13. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators. Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515 [TBL] [Abstract][Full Text] [Related]
14. Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy. Hua W; Niu H; Fan X; Ding L; Xu YZ; Wang J; Chen K; Wang F; Zhang S; J Cardiovasc Electrophysiol; 2012 Nov; 23 Suppl 1():S5-9. PubMed ID: 23140347 [TBL] [Abstract][Full Text] [Related]
15. Use of a screening tool improves appropriate referral to an electrophysiologist for implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Gravelin LM; Yuhas J; Remetz M; Radford M; Foley J; Lampert R Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):152-6. PubMed ID: 21304093 [TBL] [Abstract][Full Text] [Related]
16. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108 [TBL] [Abstract][Full Text] [Related]
17. Deactivation of implantable cardioverter-defibrillators: results of patient surveys. Herman D; Stros P; Curila K; Kebza V; Osmancik P Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573 [TBL] [Abstract][Full Text] [Related]
18. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. Rho RW; Patton KK; Poole JE; Cleland JG; Shadman R; Anand I; Maggioni AP; Carson PE; Swedberg K; Levy WC Circulation; 2012 Nov; 126(20):2402-7. PubMed ID: 23072904 [TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death after myocardial infarction: implications of international guidelines. Foley PW; Addison CE; Whinney SB; Patel K; Cunningham D; Frenneaux MP; Leyva F Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S131-4. PubMed ID: 19250076 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]